<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> are <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal disorders</z:e> which often result in significant morbidity or surgery </plain></SENT>
<SENT sid="1" pm="."><plain>Current treatment options are not curative and may cause significant adverse effects </plain></SENT>
<SENT sid="2" pm="."><plain>The introduction of anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (anti-TNFα) therapy over a decade ago was a welcome addition to the therapeutic armamentarium and revolutionized the treatment of <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e> (IBD) </plain></SENT>
<SENT sid="3" pm="."><plain>Despite their relative success, a significant proportion of patients with IBD fail to respond or subsequently lose response anti-TNFα therapy </plain></SENT>
<SENT sid="4" pm="."><plain>This review identifies and explores the role of drug levels and immunogenicity (antibody formation) on the efficacy of anti-TNFα therapy and details how monitoring these parameters may help to optimize the management of patients with IBD </plain></SENT>
</text></document>